Dana G. Mead Jr. is Director at Intersect ENT, Inc. (XENT). They have made 5 open-market trades across 5 companies since 2016, most recently 2026-06-05.
5 open-market purchases totalling $1.2M since 2016, never a sale. Across 5 scored buys the stock is up 31.5% at ninety days, and 28.1 points ahead of the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 60% | 80% | 100% |
| Avg Move | +5.3% | +10.5% | +31.5% |
| Alpha | +3.9% | +9.2% | +28.1% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| MOBI | BUY | 2026-05-11 | 2026-05-11 | $15.00 | $105K | +3.6% | +4.7% | +5.1% |
| LUNG | BUY | 2020-10-05 | 2020-10-05 | $19.00 | $500K | -9.0% | +0.1% | +28.1% |
| XENT | BUY | 2018-08-06 | 2018-08-17 | $26.22 | $200K | +9.6% | +9.6% | +15.4% |
| INSP | BUY | 2018-05-07 | 2018-05-09 | $16.00 | $320K | +37.3% | +39.4% | +90.5% |
| TDOC | BUY | 2016-03-17 | 2016-03-18 | $10.65 | $107K | -15.0% | -1.4% | +18.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| Total |
| $4.6M |
Shares reported on the most recent Form 4, priced at the 2026-06-09 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.